Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
29 patients who provided consent for the blood biomarker study, categorizing them into Grade 0–1 and Grade 2 or higher pneumonitis groups.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Further large-scale studies are needed to establish biomarkers for patients with NSCLC who receive durvalumab maintenance therapy after CCRT. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15467-0.
[INTRODUCTION] The standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 ant
APA
Yano R, Tokito T, et al. (2025). Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.. BMC cancer, 26(1), 113. https://doi.org/10.1186/s12885-025-15467-0
MLA
Yano R, et al.. "Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.." BMC cancer, vol. 26, no. 1, 2025, pp. 113.
PMID
41419873 ↗
Abstract 한글 요약
[INTRODUCTION] The standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 antibody) maintenance therapy. Biomarkers related to immune-related pneumonitis during durvalumab maintenance therapy after CCRT for stage III NSCLC have not yet been identified.
[METHODS] We evaluated 88 cytokines/chemokines at three time points, before concurrent chemoradiotherapy (pre-CCRT), post-radiotherapy, and six weeks after durvalumab administration, using a multiplex assay (Bio-Plex system) in 29 patients who provided consent for the blood biomarker study, categorizing them into Grade 0–1 and Grade 2 or higher pneumonitis groups.
[RESULTS] At pre-CCRT, no significant changes were observed; however, at post-radiotherapy, significant changes in TNFRSF8/sCD30 were observed in the group with Grade 2 or higher pneumonitis. Moreover, six weeks after durvalumab administration, significant changes were observed in TNFRSF8/sCD30, in addition to TNFSF12, IL-1Ra, CXCL9/CXCL10/CXCL11, IFN-γ, and CCL19.
[CONCLUSION] Although no biomarkers predicting Grade 2 or higher pneumonitis before CCRT were identified, the relationship between radiotherapy and TNFRSF8/sCD30 as well as the relationship between durvalumab administration and various cytokines/chemokines is reported for the first time in stage III NSCLC. In particular, the CXCL family, including CXCL9, CXCL10, and CXCL11, is considered highly significant in pneumonitis with durvalumab maintenance therapy after CCRT for stage III NSCLC. Further large-scale studies are needed to establish biomarkers for patients with NSCLC who receive durvalumab maintenance therapy after CCRT.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15467-0.
[METHODS] We evaluated 88 cytokines/chemokines at three time points, before concurrent chemoradiotherapy (pre-CCRT), post-radiotherapy, and six weeks after durvalumab administration, using a multiplex assay (Bio-Plex system) in 29 patients who provided consent for the blood biomarker study, categorizing them into Grade 0–1 and Grade 2 or higher pneumonitis groups.
[RESULTS] At pre-CCRT, no significant changes were observed; however, at post-radiotherapy, significant changes in TNFRSF8/sCD30 were observed in the group with Grade 2 or higher pneumonitis. Moreover, six weeks after durvalumab administration, significant changes were observed in TNFRSF8/sCD30, in addition to TNFSF12, IL-1Ra, CXCL9/CXCL10/CXCL11, IFN-γ, and CCL19.
[CONCLUSION] Although no biomarkers predicting Grade 2 or higher pneumonitis before CCRT were identified, the relationship between radiotherapy and TNFRSF8/sCD30 as well as the relationship between durvalumab administration and various cytokines/chemokines is reported for the first time in stage III NSCLC. In particular, the CXCL family, including CXCL9, CXCL10, and CXCL11, is considered highly significant in pneumonitis with durvalumab maintenance therapy after CCRT for stage III NSCLC. Further large-scale studies are needed to establish biomarkers for patients with NSCLC who receive durvalumab maintenance therapy after CCRT.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15467-0.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma.
- The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
- Computational analysis of multi-omics data reveals CXCL10 DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma.
- Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
- Preoperative exercise induces anti-tumor Kupffer cells to prevent surgical stress-promoted colorectal cancer liver metastasis.
- CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer.